Be. Johnson et al., MYC FAMILY DNA AMPLIFICATION IN 126 TUMOR-CELL LINES FROM PATIENTS WITH SMALL-CELL LUNG-CANCER, Journal of cellular biochemistry, 1996, pp. 210-217
We identified 126 tumor cell lines established from patients with smal
l cell cancer at the NCI-Navy Medical Oncology Branch from 1977 throug
h 1992. Extensive clinical information was available on 96 patients fr
om whom these cell lines were established. These patients comprised ap
proximately one fourth of the 407 patients treated on prospective ther
apeutic clinical trials during the same time period. The proportion of
tumor cell lines established from previously untreated patients with
both limited and extensive stage small cell lung cancer increased duri
ng the 16 years of the study (P = 0.008). MYC family DNA amplification
was present in 16 of 44 (36%) tumor cell lines established from previ
ously treated patients compared to 7 of 52 (11%) of tumor cell lines e
stablished from untreated patients (P = 0.009). MYC DNA amplification
in tumor cell lines established from patients previously treated with
chemotherapy continued to be associated with shortened survival (P = 0
.001). The initiation of a policy to obtain tumor tissue for the purpo
se of selecting chemotherapeutic agents given to individual patients w
as associated with an increase in the proportion of patients from whom
tumor cell lines could be established for both extensive and limited
stage patients (P = 0.0001 and 0.05, respectively). (C) 1996 Wiley-Lis
s, Inc.